Trump announces trade deal with EU following months of negotiations
Twist Bioscience Corp (NASDAQ:TWST) Chief Executive Officer Emily Leproust recently sold shares in the company, according to a regulatory filing. On March 20, Leproust sold 1,726 shares of Twist Bioscience at a price of $41.676 per share, totaling approximately $71,932. The stock, which currently trades at $44.94 and has a market capitalization of $2.7 billion, appears overvalued according to InvestingPro analysis.
This transaction was part of a mandatory "sell to cover" arrangement to satisfy tax withholding obligations related to the vesting of restricted stock units. Consequently, these sales were not discretionary trades by Leproust. Following this transaction, Leproust holds 660,966 shares of Twist Bioscience directly. The company maintains strong liquidity with a current ratio of 4.96, operating with moderate debt levels.
In addition to the share sale, Leproust has various employee stock options with differing conversion or exercise prices, but these were not part of the recent transaction. Analysts maintain a positive outlook with a high price target of $62, though InvestingPro data reveals 7 additional key insights about the company’s financial health and market position.
In other recent news, Twist Bioscience reported first-quarter financial results for fiscal year 2025, surpassing consensus predictions and previously issued company guidance. The company revised its full-year fiscal 2025 guidance, projecting total revenue growth of 19-21% year-over-year, an increase from the prior forecast of 17-20%. Gross margins are expected to be around 49% for the full year, with a projection of above 50% for the fourth quarter. Scotiabank (TSX:BNS) responded to these results by raising Twist Bioscience’s price target to $62, maintaining a Sector Outperform rating. Barclays (LON:BARC) also increased its price target for the company to $58, reiterating an Overweight rating, citing growing momentum in the Express portfolio and Next-Generation Sequencing tools.
Additionally, Twist Bioscience held its Annual Meeting of Stockholders, where stockholders approved an increase in authorized common stock by 100 million shares and amendments to the company’s equity incentive plan. These amendments include an increase of 3.7 million shares reserved for issuance and the removal of the "evergreen" provision. The company also amended its Charter to provide for the exculpation of certain officers from liability under specific circumstances. The meeting included the election of three directors and the ratification of Ernst & Young LLP as the independent registered accounting firm for the fiscal year ending September 30, 2025. These developments reflect Twist Bioscience’s strategic focus on growth and aligning employee and shareholder interests.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.